Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
Vamsidhar Velcheti, Pallavi Patwardhan, Frank Xiaoqing Liu, et al.
PLoS ONE (2018) Vol. 13, Iss. 11, pp. e0206370-e0206370
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Julianne D. Twomey, Baolin Zhang
The AAPS Journal (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 506
Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
J. Nicholas Bodor, Yanis Boumber, Hossein Borghaei
Cancer (2019) Vol. 126, Iss. 2, pp. 260-270
Open Access | Times Cited: 263
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
A.J. Schoenfeld, H. Rizvi, Chai Bandlamudi, et al.
Annals of Oncology (2020) Vol. 31, Iss. 5, pp. 599-608
Open Access | Times Cited: 250
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
Paula I. González-Ericsson, Elisabeth Specht Stovgaard, Luz F. Sua, et al.
The Journal of Pathology (2020) Vol. 250, Iss. 5, pp. 667-684
Open Access | Times Cited: 180
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remón, Francesco Passiglia, Myung‐Ju Ahn, et al.
Journal of Thoracic Oncology (2020) Vol. 15, Iss. 6, pp. 914-947
Open Access | Times Cited: 140
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Shengjie Tang, Chao Qin, Haiyang Hu, et al.
Cells (2022) Vol. 11, Iss. 3, pp. 320-320
Open Access | Times Cited: 130
PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer
Ryota Sumitomo, Tatsuya Hirai, Masaaki Fujita, et al.
Lung Cancer (2019) Vol. 136, pp. 136-144
Closed Access | Times Cited: 88
Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors
Regan M. Memmott, Adam R. Wolfe, David P. Carbone, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 7, pp. 1086-1098
Open Access | Times Cited: 73
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
Scott A. Tomlins, Nickolay A. Khazanov, Benjamin J. Bulen, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 25
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Lung Cancer (2020) Vol. 152, pp. 174-184
Open Access | Times Cited: 68
Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)
Mariano Provencio, Enric Carcereny, Delvys Rodríguez‐Abreu, et al.
Translational Lung Cancer Research (2019) Vol. 8, Iss. 4, pp. 461-475
Open Access | Times Cited: 59
Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review
Emily Prince, Jenine K. Sanzari, Dimple Pandya, et al.
JCO Precision Oncology (2021), Iss. 5, pp. 953-973
Open Access | Times Cited: 51
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130
Sunil Badve, Frédérique Penault‐Llorca, Jorge S. Reis‐Filho, et al.
JNCI Journal of the National Cancer Institute (2021) Vol. 114, Iss. 5, pp. 664-675
Open Access | Times Cited: 48
Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
Jake G Maule, Lani K Clinton, Ryon P. Graf, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 10, pp. e005573-e005573
Open Access | Times Cited: 30
Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
Gabriel Krigsfeld, Emily Prince, James Pratt, et al.
Journal of Clinical Pathology (2020) Vol. 73, Iss. 10, pp. 656-664
Open Access | Times Cited: 45
Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer
David Hwang, Tahani Albaqer, Rex C. Santiago, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 9, pp. 1490-1500
Open Access | Times Cited: 35
Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing–Based Tests: Challenges, Opportunities, and Potential Solutions
Patricia A. Deverka, Michael P. Douglas, Kathryn A. Phillips
Value in Health (2020) Vol. 23, Iss. 5, pp. 540-550
Open Access | Times Cited: 29
Molecular Pathology of Lung Cancer
James J. Saller, Theresa A. Boyle
Cold Spring Harbor Perspectives in Medicine (2021) Vol. 12, Iss. 3, pp. a037812-a037812
Open Access | Times Cited: 26
First-line Treatment Patterns and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden: A Population-based Real-world Study with Focus on Immunotherapy
Gunnar Wagenius, Anders Vikström, Anders Berglund, et al.
Acta Oncologica (2024) Vol. 63, pp. 198-205
Open Access | Times Cited: 3
A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer
Aurelia Noske, Johannes Ammann, Daniel‐Christoph Wagner, et al.
Histopathology (2020) Vol. 78, Iss. 4, pp. 567-577
Open Access | Times Cited: 26
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%
Andreas Kuznik, Caitlin Smare, Chieh-I Chen, et al.
Value in Health (2021) Vol. 25, Iss. 2, pp. 203-214
Open Access | Times Cited: 21
Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies
Swapnil Rajurkar, Isa Mambetsariev, Rebecca Pharaon, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 6, pp. 1870-1870
Open Access | Times Cited: 20
PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations
Mohammed S. I. Mansour, Karina Malmros, Ulrich Mager, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4517-4517
Open Access | Times Cited: 11
Trends in Real-World Biomarker Testing and Overall Survival in US Patients with Advanced Non-Small-Cell Lung Cancer
Ning Wu, Wenzhen Ge, Ruben G.W. Quek, et al.
Future Oncology (2022) Vol. 18, Iss. 39, pp. 4385-4397
Open Access | Times Cited: 11
New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?
Markus Eckstein, Shilpa Gupta
Annals of Translational Medicine (2019) Vol. 7, Iss. S3, pp. S135-S135
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top